MARKET

BMY

BMY

Bristol-Myers Squibb Co
NYSE
48.86
-0.14
-0.28%
Opening 12:37 04/24 EDT
OPEN
48.87
PREV CLOSE
48.99
HIGH
48.92
LOW
48.56
VOLUME
4.51M
TURNOVER
0
52 WEEK HIGH
70.94
52 WEEK LOW
47.03
MARKET CAP
99.02B
P/E (TTM)
12.65
1D
5D
1M
3M
1Y
5Y
Bristol-Myers Earnings Preview: Major near-term headwinds invites worries about Q1 results
Bristol-Myers Squibb Company (BMY) is scheduled to announce Q1 earnings results on Thursday, April 25th. Analysts expect a loss of -$4.42 per share on revenue of $11.45B. Cantor believes that there are major headwinds this quarter for the company.
Seeking Alpha · 8h ago
BRISTOL-MYERS DISCLOSES PRELIMINARY $6.29 GAAP & NON-GAAP EPS IMPACT FOR 3 MONTHS ENDED MARCH 31 RELATED TO ACQUIRED IPRD & LICENSING INCOME - WEBSITE
Reuters · 8h ago
S&P 500 stocks with biggest estimated EPS declines for Q1
Seeking Alpha · 1d ago
Bristol-Myers Squibb Co <BMY.N> expected to post a loss of $4.42 a share - Earnings Preview
Bristol-Myers Squibb Co expected to post a loss of $4.42 a share. The company is expected to report a 1.0% increase in quarterly revenue to $11.455 billion. The mean estimate from 17 analysts is for a quarterly revenue of $10.2 billion.
Reuters · 1d ago
Baron Health Care Fund Q1 2024 Shareholder Letter
Baron Health Care Fund advanced 8.92% in the quarter ended March 31, 2024. The Fund's performance was in line with the Russell 3000 Health Care Index and the S&P 500 Index. Investments in health care equipment, pharmaceuticals, and life sciences added the most value in the period.
Seeking Alpha · 1d ago
Gilead Q1 Earnings Preview: Most Gains Wiped Out - Cause For Concern?
Gilead Sciences, Inc. Will report its Q1 2024 earnings on Thursday, April 25. GILD stock has given up most of its late-2022 gains due to sector-wide underperformance and disappointing data from the EVOKE-01 Phase 3 trial. In this earnings preview, I take a look at the pharmaceutical company's past earnings track record and share what to expect from Gilead's Q1 earnings. I also give a brief valuation update and share whether GILD is a good buy ahead of Q1.
Seeking Alpha · 1d ago
Novartis Stock Gains On European Drugmaker's Q1 Earnings Surprise, Lifts Annual Outlook
Swiss pharma giant Novartis AG reports better-than-expected first-quarter results. First-quarter sales reached $11.83 billion, up 10% year over year and 11% on constant currency. Company raised its full-year guidance for 2024.
Benzinga · 1d ago
UPDATE 4-Novartis raises guidance after beating Q1 expectations
Novartis raises full-year guidance on wider use of psoriasis and arthritis drug Cosentyx. Swiss drugmaker beats Q1 expectations with revenue up 10% to $11.83 billion. Former boss of Bristol Myers Squibb to become Novartis chairman year.
Reuters · 1d ago
More
About BMY
Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The Company's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib.

Webull offers Bristol-Myers Squibb Co stock information, including NYSE: BMY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BMY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BMY stock methods without spending real money on the virtual paper trading platform.